CSIMarket
 


Johnson and Johnson  (JNJ)
Other Ticker:  
 

Johnson And Johnson's Leverage Ratio

JNJ's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to net new borrowings of 0.71%, Leverage Ratio fell to 1.16, above the Johnson And Johnson's average Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the forth quarter 2023, 27 other companies have achieved lower Leverage Ratio than Johnson And Johnson in the IV Quarter 2023. While Leverage Ratio total ranking has improved so far in the forth quarter 2023 to 388, from total ranking in the third quarter 2023 at 1888 .

Explain Leverage Ratio?
Who are JNJ Customers?
What are JNJ´s Total Liabilities?


JNJ Leverage Ratio (Dec 31 2023)
IV. Quarter
(Oct 01 2023)
III. Quarter
(Jul 02 2023)
II. Quarter
(Apr 02 2023)
I. Quarter
(Jan 01 2023)
IV. Quarter
Y / Y Equity Change -10.46 % -4.52 % 0.07 % -5.14 % 3.76 %
Y / Y Total Liabilities Change -11.35 % -8.65 % 14.72 % 21.66 % 1.55 %
Leverage Ratio MRQ 1.16 1.11 1.32 1.56 1.17
JNJ's Total Ranking # 388 # 1888 # 2849 # 2474 # 435
Seq. Equity Change -3.45 % -6.78 % 7.82 % -7.73 % 2.96 %
Seq. Total Liabilities Change 0.71 % -21.65 % -8.57 % 22.87 % 3.79 %



Leverage Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 28
Healthcare Sector # 64
Overall Market # 388


Leverage Ratio Statistics
High Average Low
1.56 0.96 0.5
(Apr 02 2023)   (June 30. 2006)




Financial Statements
Johnson And Johnson's Equity $ 68,774 Millions Visit JNJ's Balance sheet
Johnson And Johnson's Total Liabilities $ 79,590 Millions Visit JNJ's Balance sheet
Source of JNJ's Sales Visit JNJ's Sales by Geography


Cumulative Johnson And Johnson's Leverage Ratio

JNJ's Leverage Ratio for the trailling 12 Months

JNJ Leverage Ratio

(Dec 31 2023)
IV. Quarter
(Oct 01 2023)
III. Quarter
(Jul 02 2023)
II. Quarter
(Apr 02 2023)
I. Quarter
(Jan 01 2023)
IV. Quarter
Y / Y Equity TTM Growth -10.46 % -4.52 % 0.07 % -5.14 % 3.76 %
Y / Y Total Liabilities TTM Growth -11.35 % -8.65 % 14.72 % 21.66 % 1.55 %
Leverage Ratio TTM 1.29 1.29 1.3 1.25 1.17
Total Ranking TTM # 1507 # 2279 # 2394 # 2468 # 2740
Seq. Equity TTM Growth -3.45 % -6.78 % 7.82 % -7.73 % 2.96 %
Seq. Total Liabilities TTM Growth 0.71 % -21.65 % -8.57 % 22.87 % 3.79 %


On the trailing twelve months basis Despite of the net new borrowings of 0.71% during the twelve months period ending in IV Quarter 2023 Johnson And Johnson has managed to unchanged Leverage Ratio in the IV Quarter 2023 to 1.29, above the JNJ's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry JNJ recorded the lowest Leverage Ratio. While Leverage Ratio total ranking has improved so far to 10, from total ranking in previous 12 month period at 92.

Explain Leverage Ratio?
Who are JNJ Customers?
What are JNJ´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 1
Healthcare Sector # 1
Within the Market # 388


trailing twelve months Leverage Ratio Statistics
High Average Low
1.64 1.07 0.51
(Jul 04 2021)   (Sep. 30, 2006)




Companies with similar Leverage Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Leverage RatioDec 31 2023 MRQ Total LiabilitiesDec 31 2023 MRQ Equity
Travere Therapeutics Inc   2.93 $ 588.103  Millions$ 200.810  Millions
Clene Inc   2.91 $ 38.951  Millions$ 13.390  Millions
Arcutis Biotherapeutics Inc   2.85 $ 252.698  Millions$ 88.667  Millions
Soligenix inc   2.84 $ 7.153  Millions$ 2.522  Millions
Aytu Biopharma Inc   2.80 $ 92.052  Millions$ 32.853  Millions
G1 Therapeutics Inc   2.43 $ 86.154  Millions$ 35.386  Millions
Proqr Therapeutics N v   2.33 $ 108.072  Millions$ 46.357  Millions
Phibro Animal Health Corporation  2.31 $ 626.625  Millions$ 270.803  Millions
Vaxxinity Inc   2.30 $ 30.902  Millions$ 13.409  Millions
Bristol myers Squibb Company  2.23 $ 65,729.000  Millions$ 29,485.000  Millions
Casi Pharmaceuticals inc   2.11 $ 51.103  Millions$ 24.165  Millions
Eyenovia inc   2.05 $ 18.488  Millions$ 8.999  Millions
Alimera Sciences Inc   2.00 $ 92.218  Millions$ 46.170  Millions
Biovie Inc   1.87 $ 13.981  Millions$ 7.491  Millions
Zoetis Inc   1.86 $ 9,289.000  Millions$ 4,991.000  Millions
Emergent Biosolutions Inc   1.81 $ 1,173.900  Millions$ 649.300  Millions
Jazz Pharmaceuticals Plc  1.78 $ 6,644.680  Millions$ 3,736.997  Millions
Catalent Inc   1.71 $ 6,301.000  Millions$ 3,687.000  Millions
Xoma Corporation  1.64 $ 145.580  Millions$ 88.721  Millions
Summit Therapeutics Inc   1.61 $ 125.257  Millions$ 77.692  Millions
Cumberland Pharmaceuticals Inc  1.59 $ 46.528  Millions$ 29.260  Millions
Merck and Co Inc   1.58 $ 59,431.000  Millions$ 37,635.000  Millions
Pfizer Inc  1.54 $ 137,487.000  Millions$ 89,288.000  Millions
Ocular Therapeutix Inc   1.54 $ 139.916  Millions$ 91.131  Millions
Liquidia Corporation  1.50 $ 71.039  Millions$ 47.293  Millions
Lexicon Pharmaceuticals Inc   1.46 $ 136.319  Millions$ 93.110  Millions
Viatris Inc   1.33 $ 27,218.100  Millions$ 20,467.400  Millions
Lifevantage Corp  1.30 $ 35.375  Millions$ 27.307  Millions
Pds Biotechnology Corp  1.27 $ 33.259  Millions$ 26.131  Millions
Verastem inc   1.24 $ 71.185  Millions$ 57.374  Millions

Date modified: 2024-02-17T12:25:26+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com